The pharmaceutical industry has been experiencing a paradigm shift with the emergence and growth of pharma franchise companies. These companies have become vital to the healthcare sector, offering ...

Aside from the CF franchise challenges, the company recently acquired additional royalties, and our team is optimistic about Royalty Pharma executing new deals. Biopharma companies' increasing ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focusing on developing ... Growing demand for its Cystic Fibrosis (CF) franchise continued to generate substantial ...

Danam's registration statement named several former executives of the $10 billion retail pharmacy franchise of pharma heavyweight McKesson. Raymond James to launch ETF platform, hires former ...

Management noted Vertex CF ... Royalty Pharma delivered strong Q1 2025 results with double-digit growth in Royalty Receipts and significant capital returns through share buybacks. The company ...